Pioneering HERV-targeted autoimmune therapies
GeNeuro (geneuro.com) scores 51 out of 100 on Brand Analyzer, placing it in the Early Stage tier among Healthcare brands, in the 2nd percentile of 19612 Healthcare brands.
GeNeuro is a biopharmaceutical company headquartered in Plan-les-Ouates, Switzerland, focused on developing novel treatments for autoimmune diseases. The company's proprietary approach targets Human Endogenous Retrovirus (HERV) mechanisms believed to trigger the onset and progression of these diseases. GeNeuro's target audience includes patients with autoimmune conditions, medical researchers, healthcare providers, and biopharmaceutical investors. As of July 2024, the company obtained court approval in Geneva for a debt-restructuring moratorium.
| Brand Name | GeNeuro |
|---|---|
| Domain | geneuro.com |
| Industry | Healthcare |
| Headquarters | Plan-les-Ouates |
| Main Competitors | Biogen (78/100), Novartis (75/100), Roche (81/100), Sanofi (90/100), Merck KGaA (86/100) |
Moz Domain Authority 39/100 vs category average 40 / leader 95 - limited third-party links, so AI systems rarely encounter mentions of the brand.
No Wikipedia presence was found - a major gap, since Wikipedia is among the most heavily weighted sources in AI training data.
The homepage meta description reads "The Geneva Court of First Instance has approved its application for a debt-restructuring moratorium dated July 15, 2024," (Meta description: 18 words (ideal length). OG description present and descriptive) - this is the summary AI engines are most likely to quote.
Structured data on the homepage: og:title, og:description. Adding Organization and FAQ schema would further help AI crawlers parse the brand's identity.
AI-crawler access: No robots.txt found (default: all bots allowed, but explicit file preferred) - robots.txt controls whether engines like GPTBot and ClaudeBot can read the site at all.
Detected tech stack: WordPress.
Social footprint: verified profiles on X (Twitter), LinkedIn, Facebook, Instagram, YouTube, GitHub - consistent profiles reinforce the brand's identity across the web.
0 Reddit mentions - community discussion signals real-world reputation to AI models.
Live results from asking a general-purpose AI assistant about the brand, checked October 2026.
When asked "What is GeNeuro?", Claude could identify the brand as of October 2026. GeNeuro is a Swiss-French clinical-stage biopharmaceutical company focused on the role of human endogenous retroviruses (HERVs) in diseases, most notably multiple sclerosis, with its lead candidate temelimab targeting an envelope protein expressed by these retroviruses. Best known for Research into HERVs and the development of temelimab for multiple sclerosis.
When asked "Best brands similar to GeNeuro?", Claude would recommend GeNeuro as of October 2026. It's a notable niche player in HERV-related drug development, relevant if someone is asking about innovative approaches to autoimmune or neurological disease treatment.
Common questions people ask in Google, ChatGPT, Claude, Gemini, Perplexity, and other AI search engines.
GeNeuro's main competitors in Healthcare: Biogen (78/100), Novartis (75/100), Roche (81/100), Sanofi (90/100), Merck KGaA (86/100).
Sources: Brand Analyzer scan
GeNeuro has low AI-search visibility, scoring 21/100 on Brand Analyzer's AI visibility composite (visibility 21, trust 15, recommendation 30). This estimates how likely AI engines like ChatGPT, Claude, Gemini and Perplexity are to know, trust, and recommend the brand.
Sources: GeNeuro official site
GeNeuro is headquartered in Plan-les-Ouates. GeNeuro operates in the Healthcare category.
Sources: Wikidata
GeNeuro scores 30/100 on Brand Analyzer's AI recommendation signal, indicating it is less likely to be surfaced when AI assistants like ChatGPT suggest Healthcare options. Recommendation depends on crawlability, structured data, and category authority.
Sources: GeNeuro official site
GeNeuro is a biopharmaceutical company based in Plan-les-Ouates, Switzerland, that develops novel treatments for autoimmune diseases using a proprietary approach targeting Human Endogenous Retroviruses (HERVs).
Sources: GeNeuro official site
GeNeuro develops therapeutic treatments for autoimmune diseases by targeting and blocking Human Endogenous Retrovirus (HERV) mechanisms that are suspected of triggering the onset and progression of these conditions. The company applies this HERV-based approach as a differentiated strategy compared to conventional autoimmune disease treatments.
Sources: GeNeuro official site
GeNeuro can improve AI discoverability by strengthening structured data (Organization and FAQ schema), maintaining an accurate Wikipedia/Wikidata entity, earning authoritative citations, and keeping content crawlable for AI bots. Brand Analyzer measures these as visibility, trust, and recommendation signals.
Sources: GeNeuro official site
GeNeuro is known for its proprietary HERV (Human Endogenous Retrovirus) approach to treating autoimmune diseases, positioning itself as a pioneer in this specific area of immunological research and therapy development.
Sources: GeNeuro official site
GeNeuro's work is relevant to patients suffering from autoimmune diseases, medical researchers studying immunological mechanisms, healthcare providers treating autoimmune conditions, and biopharmaceutical investors interested in novel immunological treatment approaches.
Sources: GeNeuro official site
GeNeuro scores 21/100 for AI visibility - how well ChatGPT, Claude, Perplexity and Google AI Overviews can discover, identify and cite the brand.
GeNeuro has a weak AI-visibility profile at 21/100 - a proxy for how readily ChatGPT, Perplexity and Google's AI Overviews can recognise and cite it. Its strongest area is recommendation likelihood (30/100) and its weakest is trust (15/100). It benefits from a Wikidata knowledge-graph entry and open access for AI crawlers (GPTBot, ClaudeBot, etc.). The main gaps holding it back: no clear Wikipedia entity to anchor it in LLM training data, a low Moz Domain Authority of 39/100 and thin schema.org structured data. In a live check, Claude could already identify GeNeuro from memory (October 2026) - a sign these signals are paying off.
The score combines seven dimensions - name quality, digital presence, visual identity, messaging clarity, trust foundation, AI discoverability, and brand authority - into a single objective benchmark.
Ranked closest to GeNeuro: Nordson MEDICAL (51/100), Fimar Spa (51/100), Genstar Capital (51/100), International Federation on Ageing (51/100).
A step up - brands to learn from: Zavod za socijalno osiguranje (56/100), Dorow Clinic (56/100).
Category leader: Booksy (96/100).
Brand Analyzer is built by DataEase AI. Track your brand in ChatGPT, Gemini and Perplexity.